



EASL CONGRESS

Consensus Conference

6 May 2025, 9:30 - 17:30 CEST

Trial design and end-points in HCC



**EUR
102.85**

Organised by EASL, AASLD, ASCO and ILCA

Join us for a high-impact, one-day event dedicated to redefining clinical trial design and end-points in HCC.

Building on recent breakthroughs, we will focus on what truly defines clinical benefit, set new standards for upcoming Phase III trials, and explore innovative regulatory strategies.

Steering Committee



Josep M. Llovet
Chair



Richard Finn
Co-chair



Tim Meyer
Co-chair



Arndt Vogel
Co-chair



Amit Singal
Co-chair

Register now:







EASL CONGRESS

Consensus Conference

6 May 2025, 9:30 - 17:30 CEST

Trial design and end-points in HCC



Explore an unmatched programme!

- ✓ Session 1: A thorough review of regulatory oncology end-points including OS, PFS, TTP, ORR, and PROs.
- ✓ Session 2: Key discussions on early and intermediate HCC trial designs, end-point selections, and regulatory considerations.
- ✓ Session 3: Advanced HCC trial strategies emphasising survival outcomes, patient stratification, and clinical relevance.
- ✓ Session 4: Emerging topics such as biomarker use, patient quality-of-life assessment, and strategies to address disparities and patient engagement in clinical trials.



Discover multi-perspective approaches from academia, regulatory bodies, and patient representatives.



Outcomes from the event will form the basis of a published consensus manuscript.

Organised by:



With support from:

